Phaseline

Targets › CRHR1

CRHR1 (Corticotropin-releasing hormone receptor 1): drug programs, companies and trials

4 programs from 4 companies in 6 trials: 4 Phase 2, 2 Phase 3; Respiratory, Genitourinary; next expected readout Dec 2026.

G protein-coupled receptor for CRH and UCN stress hormones, which plays a central role in whole body adaptation to stress. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and downstream effectors, such as adenylate cyclase. (UniProt, P34998)

Open in Phaseline: the race on CRHR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Neurocrine BiosciencesCrinecerfont
Corticotropin releasing factor receptor 1 antagonist
CRHR1Phase 3Congenital Adrenal HyperplasiaAug 2027
ShionogiSivopixant
CRF1 receptor antagonist
CRHR1Phase 2Sleep ApneaDec 2026
Chiesi FarmaceuticiCHF5993 pMDI 100/6/12.5 µg with HFA-152a
Triple combination: inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA), long-
ADRB2, CRHR1Phase 2AsthmaJun 2027
Neurocrine SwitzerlandCrinecerfont
Corticotropin releasing factor receptor 1 antagonist
CRHR1Phase 2Congenital Adrenal HyperplasiaMar 2028

Conditions

Congenital Adrenal Hyperplasia (4) Asthma (1) Sleep Apnea (1)

Modalities

small molecule (4)

Companies

Chiesi Farmaceutici (1) Neurocrine Switzerland (1) Shionogi (1) Neurocrine Biosciences (1)

Related targets

ADRB2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.